Arax Advisory Partners’s Protalix BioTherapeutics PLX Stock Holding History

Arax Advisory Partners’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.59K	Buy	1,112 +1,057	+1,922%	+$2.24K	﹤0.01%	4763
2026 Q1	$120	Buy	55 +16	+41%	+$40	﹤0.01%	3596
2025 Q4	$71	Sell	39 -257	-87%	-$525	﹤0.01%	3877
2025 Q3	$658	Buy	+296	New	+$482	﹤0.01%	3337
2025 Q1	–	Sell	-39	Closed	-$74	–	2958
2024 Q4	$74	Hold	39	–	–	﹤0.01%	2401
2024 Q3	$40	Hold	39	–	–	﹤0.01%	2592
2024 Q2	$46	Buy	+39	New	+$46	﹤0.01%	2516

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Arax Advisory Partners's PLX Position: Q2 2026 in Review

Arax Advisory Partners increased its Protalix BioTherapeutics (PLX) stake by 1,922% in Q2 2026, buying an estimated $2.24K and bringing the position to 1,112 shares worth $2.59K. The position accounts for ﹤0.01% of the portfolio, ranked #4763.

Arax Advisory Partners first reported a position in PLX in Q2 2024 and has held it in 7 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Arax Advisory Partners held 1,112 shares of Protalix BioTherapeutics worth $2.59K as of Q2 2026.
Arax Advisory Partners bought 1,057 Protalix BioTherapeutics shares in Q2 2026, an estimated $2.24K.
Protalix BioTherapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4763 holding.
Arax Advisory Partners first reported a position in Protalix BioTherapeutics in Q2 2024 and has held it in 7 quarters since.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.